Compare DNA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNA | CMPX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 408.8M |
| IPO Year | 2020 | 2020 |
| Metric | DNA | CMPX |
|---|---|---|
| Price | $6.94 | $2.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $8.50 | ★ $14.57 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $170,155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $934.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.37 | $1.61 |
| 52 Week High | $17.58 | $6.88 |
| Indicator | DNA | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 45.53 |
| Support Level | $6.30 | $1.88 |
| Resistance Level | $7.10 | $2.23 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 27.47 | 2.90 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.